Coldpine is shutting down on November 24, 2026. Account data will be deleted after that date. Questions: hello@coldpine.io
 

ABBV Congressional Stock Trades

ABBVIE INC

Last disclosed trade Oct 7

Every disclosed trade in ABBV by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice. See every healthcare stock Congress trades.

Sample · the intelligence layer

Coldpine signal scoreA 0-1 composite from four weighted factors: disclosure speed, trade size, cluster activity (multiple members buying the same name), and the member’s track record. ≥ 0.65 is the high-score tier; ≥ 0.50 is moderate. Trades from trust-managed members are penalized (× 0.2 multiplier). It’s research, not a recommendation.

Pete Sessions · Sold $ABBV · Sep 14 · $15K–$50K

0.65HIGH
Disclosure speedx 0.251.00
Trade sizex 0.250.50
Cluster activityx 0.150.00
Track recordx 0.350.79

Coldpine’s read

Sessions sits on Financial Services and Oversight, though neither directly oversees pharmaceutical firms like AbbVie. The sale falls in the moderate $15K–$50K range and was held in an IRA subaccount. The 4-day disclosure lag is relatively fast, meaning the market may not have fully absorbed the filing.

Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →

Follow $ABBV

Get notified when any member of Congress trades $ABBV. Free, no card, no spam.

Follow free →
59
Disclosed trades
31
Buys
28
Sales
13
Members trading

The record on $ABBV

Coldpine has parsed 59 disclosed trades in $ABBV by 13 members of Congress, drawn from 44 periodic transaction reports dated Feb 10, 2023 through Oct 7, 2026. That is 58 trades from House members and 1 trade from senators, filed 46 by Democrats and 13 by Republicans.

Of the 59 trades with a known filing lag, 1 was reported more than 45 days after the trade date, outside the window the STOCK Act sets. The median lag was 26 days. The longest was 116 days: a $ABBV purchase by Alan Armstrong dated Mar 27, 2026, disclosed Jul 21, 2026. How late filing is measured across all of Congress is in the late-filers study.

45 of the 48 trades that list an account holder (94%) were reported under a spouse, dependent child, or joint account rather than the member directly.

Rohit Khanna filed the most $ABBV purchases (17), and Rohit Khanna the most sales (18).

Activity peaked in 2025 with 19 trades. The busiest single month was May 2025, when 3 different members disclosed $ABBV trades. In 1 calendar month out of 30 with activity, three or more members bought $ABBV in the same month, the same-direction overlap Coldpine's cluster detector looks for.

Across the 31 purchases Coldpine can price, $ABBV moved +3.44% on average between the trade date and the disclosure date, against +1.27% for the S&P 500 over the same windows. The stock was higher at disclosure than at the trade in 68% of those purchases. That is a record of what already happened, not a forecast. Method: what stocks do before Congress discloses.

Members who trade ABBV

Recent disclosed trades in ABBV

DateMemberTypeAmount
Oct 7Rohit Khanna(CA)buy$1K–$15K
Sep 14Pete Sessions(TX)sell$15K–$50K
Sep 4Rohit Khanna(CA)sell$15K–$50K
Jun 2Rohit Khanna(CA)buy$1K–$15K
May 5Josh Gottheimer(NJ)sell$1K–$15K
Apr 13Rohit Khanna(CA)sell$15K–$50K
Mar 27Alan Armstrong(OK)buy$15K–$50K
Aug 4Marjorie Taylor Greene(GA)buy$1K–$15K
Jul 1Rohit Khanna(CA)sell—
May 28Rohit Khanna(CA)buy$15K–$50K
May 22Josh Gottheimer(NJ)buy$1K–$15K
May 15Rob Bresnahan(PA)buy$1K–$15K
Apr 7Jared Moskowitz(FL)buy$1K–$15K
Apr 3Dwight Evans(PA)sell$1K–$15K
Mar 17Marjorie Taylor Greene(GA)buy$1K–$15K
Mar 6Rohit Khanna(CA)buy$1K–$15K
Feb 19Rohit Khanna(CA)buy$15K–$50K
Feb 5Rohit Khanna(CA)sell$1K–$15K
Feb 5Rohit Khanna(CA)sell$1K–$15K
Feb 5Rohit Khanna(CA)sell$1K–$15K

Showing 20 of 59 disclosed trades.

Sign up free for the full history, signal scores, the price-vs-trades chart, and Coldpine's read (the AI narrative on each trade).

Create a free account

From Coldpine Research

Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →